Kolosis BIO — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Kolosis BIO is a private, commercial-stage company founded in 2020 that acts as the exclusive commercial partner for MTF Biologics' portfolio of allograft-based orthobiologics. The company leverages established distribution agreements and a network of over 400 independent distributors to place its grafts in over 5,800 facilities across the US and Canada, with products used in over 35,000 fusion procedures. Positioning itself as a responsive alternative to larger competitors, Kolosis emphasizes relentless execution, scientific support, and deep compliance while building a portfolio around MTF's 30+ years of tissue processing expertise.

OrthopedicsSpine SurgeryWound CarePlastic & Reconstructive Surgery

Technology Platform

Exclusive commercial partner for MTF Biologics' allograft processing platform, which utilizes proprietary aseptic processing to preserve biological matrices and proteins in donated human tissue for use in bone grafts and extracellular matrices.

Opportunities

The company has a significant opportunity to deepen market penetration within its existing network of over 5,800 facilities and expand internationally.

Continued launch of new products from MTF's pipeline, like APEXecm, allows it to address adjacent surgical needs and drive growth.

Its partnership model and focus on execution position it well to capture share from larger, less agile competitors in the orthobiologics market.

Risk Factors

The company faces extreme concentration risk due to complete dependence on its single partner, MTF Biologics.

It operates in a fiercely competitive market against large, integrated medical device companies with greater resources.

Additionally, the business is exposed to regulatory compliance risks inherent in selling biologic products and managing distributor relationships.

Competitive Landscape

Kolosis competes in the orthobiologics market against large, diversified players like Medtronic, Stryker, Johnson & Johnson (DePuy Synthes), and Zimmer Biomet, which have extensive portfolios and direct sales forces. It also competes with other allograft processors and distributors. Its differentiation is its exclusive focus on MTF products, a partnership-driven commercial model, and claimed superior responsiveness.

More companies in Biologics / Biosimilars →More companies in United States →